Carlumab是一种人源化、高亲和力的抗CCL2。
Cas No.:915404-94-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Carlumab is a humanized, high-affinity monoclonal antibody that targets CCL2[1-2]. Carlumab exerts its effects by specifically binding to and neutralizing CCL2, thereby inhibiting the recruitment and migration of monocytes/macrophages to the tumor microenvironment and reducing angiogenesis. Carlumab has been investigated in research related to solid tumors such as prostate cancer, ovarian cancer, and glioblastoma, as well as idiopathic pulmonary fibrosis[3-4].
In vitro, human peritoneal mesothelial cells were pretreated with Carlumab (30μg/mL) for 30 minutes, followed by stimulation for 24 hours with a medium containing 0.1% SHS (containing chlorhexidine) and 1μg/mL LPS. Carlumab significantly attenuated the migration of THP-1-derived macrophages towards the injured site in the co-culture system[5]. Endometrial cancer cells were treated with Carlumab (5μg/mL) for 24 hours. This treatment was able to neutralize tumor cell-secreted CCL2, significantly inhibiting the migration of THP-1-derived macrophages towards the tumor cells[6].
In vivo, Carlumab (20mg/kg) was administered via intraperitoneal injection to BALB/c nude mice bearing KLE cell xenograft tumors for 29 days. Carlumab treatment effectively reduced tumor volume, decreased serum CCL2 levels, and reduced the infiltration of CD163+ and CD115+ M2-type macrophages within the tumor tissue[6].
References:
[1] Brana I, Calles A, LoRusso PM, et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
[2] Raghu G, Martinez FJ, Brown KK, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015 Dec;46(6):1740-50.
[3] Fetterly GJ, Aras U, Meholick PD, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53(10):1020-7.
[4] Wang C, Wang L, Li Q, et al. Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis. World Neurosurg. 2023 Jun;174:e8-e16.
[5] Sun J, Sun Y, Guo D, et al. Targeting STING to disrupt macrophage-mediated adhesion in encapsulating peritoneal sclerosis. Commun Biol. 2025 Aug 23;8(1):1266.
[6] Ma J, Mao X, Ren Y, et al. Antagonism of estrogen-related receptor-α inhibits mitochondrial oxidative phosphorylation and reduces M2 macrophage infiltration in endometrial cancer. J Immunother Cancer. 2025 Sep 29;13(9):e012521.
Carlumab是一种人源化、高亲和力的抗CCL2[1-2]。Carlumab通过特异性结合并中和CCL2，从而抑制单核细胞/巨噬细胞向肿瘤微环境的募集和迁移，并减少血管生成。Carlumab可用于前列腺癌、卵巢癌、胶质母细胞瘤等实体瘤以及特发性肺纤维化的相关研究[3-4]。
在体外，Carlumab（30μg/mL）处理人腹膜间皮细胞30分钟，随后以含有0.1% SHS（含氯己定）和1μg/mL LPS的培养基刺激24小时。Carlumab可显著抑制共培养系统中THP-1源性巨噬细胞向损伤部位的迁移[5]。Carlumab（5μg/mL）处理子宫内膜癌细胞24小时。Carlumab能够中和肿瘤细胞分泌的CCL2，从而显著抑制共培养系统中THP-1源性巨噬细胞向肿瘤细胞的迁移[6]。
在体内，Carlumab（20mg/kg）腹腔注射于携带KLE细胞异种移植瘤的BALB/c裸鼠。Carlumab能够有效减少肿瘤体积、降低血清CCL2水平，并减少肿瘤组织中的CD163+和CD115+ M2型巨噬细胞浸润[6]。
| Cell experiment [1]: | |
Cell lines | Human peritoneal mesothelial cells (HPMCs) and PMA-differentiated THP-1 macrophages |
Preparation Method | HPMCs were cultured in M199 medium supplemented with 10% FBS. To simulate EPS conditions, HPMCs in the lower chamber of a Trans-well system were treated with 0.1% SHS and 1μg/mL LPS. Carlumab (30μg/mL) or an anti-IgG control was added to the HPMCs 30 minutes prior to the EPS stimulation. PMA-differentiated THP-1 macrophages were seeded in the upper chamber. |
Reaction Conditions | 30μg/mL; pretreatment for 30min. |
Applications | Pretreatment with Carlumab significantly attenuated the migration of macrophages towards the EPS-stimulated mesothelial cells in the co-culture system. |
| Animal experiment [2]: | |
Animal models | Female BALB/c nude mice (aged 4-5 weeks) bearing KLE cell xenograft tumors. |
Preparation Method | KLE cells were transplanted into the forelimb armpit of mice to establish a xenograft model. Mice were administered physiological saline, Carlumab, the ERRα inhibitor XCT790, or a combination of Carlumab (20mg/kg) and XCT790 via intraperitoneal injection for 29 days. |
Dosage form | 20mg/kg; i.p.; for 29 days. |
Applications | Carlumab administration, either alone or in combination with XCT790, significantly reduced tumor volume, decreased serum CCL2 levels, and reduced the infiltration of CD163+ and CD115+ M2-type macrophages within the tumor tissue. |
References: | |
| Cas No. | 915404-94-3 | SDF | Download SDF |
| 别名 | CNTO 888 | ||
| 分子式 | 分子量 | 114.87 kDa | |
| 溶解度 | 储存条件 | Store at -80°C for 2 years. | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.7 μL | 43.5 μL | 87.1 μL |
| 5 mM | 1.7 μL | 8.7 μL | 17.4 μL |
| 10 mM | 0.9 μL | 4.4 μL | 8.7 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >97.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet